Press Releases
15.04.2013
The Paul-Ehrlich Institute has granted approval for a phase I clinical study of a gene therapy with MGN1404 for the treatment of melanomas. The study is entitled "Phase I trial of TNF-alpha expressing MIDGE-vector non-viral gene transfer in...
21.03.2013
The Berlin biotechnology company MOLOGEN AG looks back on an extremely successful 2012 financial year. The company made great progress with regard to both research activities for the core product candidates, MGN1703 and MGN1601, and company...
Contact:
Prof. Peter W. Hübner
Head of Corporate Communications
T. +49 (0) 30 - 84 17 88 - 38
F. +49 (0) 30 - 84 17 88 - 50
M. +49 (0) 171 900 10 77